Anacor Pharma (ANAC) Misses Q3 EPS by 11c

Anacor Pharma (NASDAQ: ANAC) reported Q3 EPS of ($0.37), $0.11 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $24.6 million versus the consensus estimate of $25.6 million.

Anacor expects to submit a New Drug Application for crisaborole topical ointment, 2%, to the U.S. Food and Drug Administration in the first quarter of 2016

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• Beike (BEKE) PT Raised to $23 at Morgan Stanley